The chemicals listed above are primarily inhibitors of enzymes involved in histone methylation and chromatin remodeling, which indirectly impact the functional context of DPY-30. DPY-30's primary role is associated with the regulation of histone H3 methylation at lysine 4 (H3K4), a key process in chromatin modification and gene expression. The inhibitors mentioned target enzymes like EZH2, a part of the Polycomb Repressive Complex 2 (PRC2), which mediates histone H3 lysine 27 (H3K27) methylation, and DOT1L, responsible for histone H3 lysine 79 (H3K79) methylation. By inhibiting these enzymes, the chemicals indirectly influence the chromatin state, which could affect DPY-30's activity.
In addition to these, the list includes several histone deacetylase (HDAC) inhibitors like Entinostat, Vorinostat, Panobinostat, and Romidepsin. HDACs are crucial for the removal of acetyl groups from histone tails, a process opposite to acetylation, which is closely linked to gene silencing. The inhibition of HDACs results in a more open chromatin structure, potentially influencing the regulatory role of DPY-30 in gene expression. These inhibitors, though not directly targeting DPY-30, provide an indirect approach to modulate the protein's activity by altering the chromatin state and histone modification patterns. This approach underscores the complexity of targeting specific proteins in chromatin biology and the need for a broader understanding of the interconnected pathways and processes. It's important to note that the effects of these inhibitors on DPY-30's function are inferred based on their known actions on chromatin and histone modifications, and direct effects on DPY-30 may not be established.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GSK343 | 1346704-33-3 | sc-397025 sc-397025A | 5 mg 25 mg | $151.00 $461.00 | 1 | |
Selective inhibitor of EZH2, leading to reduced histone H3K27 methylation, indirectly affecting pathways where DPY-30 is involved. | ||||||
EPZ6438 | 1403254-99-8 | sc-507456 | 1 mg | $66.00 | ||
Inhibits EZH2, altering histone methylation patterns, which may indirectly modulate DPY-30's activity in gene regulation. | ||||||
UNC1999 | 1431612-23-5 | sc-475314 | 5 mg | $142.00 | 1 | |
A dual inhibitor of EZH2 and EZH1, impacting histone methylation and potentially influencing DPY-30's functional context. | ||||||
GSK126 | 1346574-57-9 | sc-490133 sc-490133A sc-490133B | 1 mg 5 mg 10 mg | $92.00 $243.00 $306.00 | ||
Highly selective inhibitor of EZH2, affecting histone methylation and potentially DPY-30 related processes. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
Inhibits HDACs, leading to alterations in chromatin structure and potentially affecting DPY-30's role. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $200.00 | 9 | |
A potent HDAC inhibitor, influencing chromatin structure and potentially affecting DPY-30's functionality. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $218.00 $634.00 | 1 | |
Inhibits HDACs, leading to changes in chromatin architecture, potentially impacting DPY-30 related processes. | ||||||